It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Growing evidence supports the importance of the p53 tumor suppressor in metabolism but the mechanisms underlying p53-mediated control of metabolism remain poorly understood. Here, we identify the multifunctional E4F1 protein as a key regulator of p53 metabolic functions in adipocytes. While E4F1 expression is upregulated during obesity, E4f1 inactivation in mouse adipose tissue results in a lean phenotype associated with insulin resistance and protection against induced obesity. Adipocytes lacking E4F1 activate a p53-dependent transcriptional program involved in lipid metabolism. The direct interaction between E4F1 and p53 and their co-recruitment to the Steaoryl-CoA Desaturase-1 locus play an important role to regulate monounsaturated fatty acids synthesis in adipocytes. Consistent with the role of this E4F1-p53-Steaoryl-CoA Desaturase-1 axis in adipocytes, p53 inactivation or diet complementation with oleate partly restore adiposity and improve insulin sensitivity in E4F1-deficient mice. Altogether, our findings identify a crosstalk between E4F1 and p53 in the control of lipid metabolism in adipocytes that is relevant to obesity and insulin resistance.
The p53 tumor suppressor is also a regulator of metabolism, but the mechanisms controlling p53-associated metabolic activities remain poorly understood. Here the authors report that the deletion of the multifunctional protein E4F1 is protective against diet-induced obesity in mice, and E4F1 regulates adipocyte lipid metabolism through p53.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France (GRID:grid.488845.d) (ISNI:0000 0004 0624 6108); Equipe labélisée Ligue Contre le Cancer, Paris, France (GRID:grid.488845.d)
2 KU Leuven–University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
3 IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France (GRID:grid.488845.d) (ISNI:0000 0004 0624 6108)
4 I2MC, Institute of Metabolic and Cardiovascular Diseases, Université de Toulouse, INSERM, Université Toulouse III – Paul Sabatier (UPS), Toulouse, France (GRID:grid.462178.e) (ISNI:0000 0004 0537 1089)
5 KU Leuven–University of Leuven, Department of Cellular and Molecular Medicine, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
6 University of Malaga, Department of Surgical Specialties, Biochemistry and Immunology School of Medicine, Malaga, Spain (GRID:grid.10215.37) (ISNI:0000 0001 2298 7828)
7 Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, CNRS, U1283 - UMR 8199 - EGID, Lille, France (GRID:grid.410463.4) (ISNI:0000 0004 0471 8845)
8 IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Univ Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France (GRID:grid.488845.d) (ISNI:0000 0004 0624 6108); BioCampus, RHEM, Université de Montpellier, CNRS, INSERM, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
9 CIBER of Physiopathology, Obesity and Nutrition (CIBEROBN), Málaga, Spain; Unidad de Gestion Clinica de Endocrinologia y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clinico Virgen de la Victoria, Málaga, Spain (GRID:grid.452525.1)
10 I2MC, Institute of Metabolic and Cardiovascular Diseases, Université de Toulouse, INSERM, Université Toulouse III – Paul Sabatier (UPS), Toulouse, France (GRID:grid.462178.e) (ISNI:0000 0004 0537 1089); Toulouse University Hospitals, Department of Clinical Biochemistry, Toulouse, France (GRID:grid.508721.9)
11 Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204)